Most GLP-1 obesity drugs hit a receptor that lives in the gut and on widely distributed peripheral and central neurons. Neuromedin U receptor 2 sits somewhere quieter. The receptor is expressed almost exclusively in the hypothalamus, the same brain region that runs the body's set point for energy and appetite. An agonist that activated NMUR2 without touching anything else would, in principle, suppress appetite from the inside without the systemic exposure that GLP-1 drugs accept as a feature. That is the long-running case for NMUR2 as a non-GLP-1 obesity target.
The problem with the case has always been delivery. Neuromedin U itself is a small peptide, easily chewed up by serum and brain proteases, and the receptor it must hit lives behind the blood-brain barrier. A team based in Japan reported in Molecular Pharmaceutics ↗ this week that the workaround is straightforward in concept and depends on a single variable in practice. The variable is peptide stability.
The group tested two of their own NMUR2-selective agonist peptides, called CPN-116 and CPN-219. Both are medium-sized; the abstract does not pin the length, but both are short enough to fit through nasal mucosa and into the olfactory pathway that bypasses the blood-brain barrier directly. The two peptides differ on one axis: how long each one survives in the compartments it has to cross. The team measured the half-life of each in serum, cerebrospinal fluid, brain homogenate, and nasal cavity homogenate. CPN-219 outlasted CPN-116 in every compartment.
The group then gave both peptides to mice, either intranasally or intraperitoneally, and measured the resulting brain concentrations and body weight curves. Two clean patterns came out. The intranasal route produced higher brain concentrations than the intraperitoneal route for both peptides; the route worked. The more stable peptide produced higher brain concentrations than the less stable peptide after intranasal dosing; stability mattered. The weight curve followed the same hierarchy. Nasal beat intraperitoneal. The stable peptide beat the less stable peptide. Stability rank predicted brain rank predicted weight rank.
The implication is small but specific. For medium-sized peptide agonists at central targets, the nasal-to-brain route can carry the peptide. Whether the peptide arrives in enough quantity to engage the target is set by what the peptide survives along the way: the nasal cavity, the olfactory mucosa, the cribriform plate, and the brain interstitium. The CPN-116 to CPN-219 comparison is a single-variable experiment on that survival. The team did not redesign the receptor binding or the route geometry. They redesigned the peptide for stability and watched the rest of the delivery chain pass the gains through to the weight curve.
A note on the broader field. Several groups have spent the last decade chasing NMUR2 as the "GLP-1 without the GLP-1 side effects" target. Some have tried full-length NMU analogs. Some have tried truncated peptides. Some have tried small molecules. None has reached a clinical trial, in part because keeping the agonist intact long enough to reach the hypothalamus is the same problem the CPN program just dissected. The current paper does not solve obesity. It does take one variable out of the way and leave the field one step closer to a peptide drug aimed at the hypothalamus by the nasal route.
The receptor does not yet have a target page on peptidemodel, and the CPN compounds are research-grade. The result that travels is the dependency, not the compound. For a peptide drug aiming at a central receptor by the nasal route, in vitro stability is the variable that picks up the efficacy. The Japanese group's successor candidate, when it comes, will have to clear this bar before any of the downstream questions about receptor selectivity, dosing window, and tolerance get to matter.